Summary

We use the most thorough and iterative research technique available, with a primary focus on offering the most precise market projections and research data content to help you develop previously unheard-of levels of business acumen. The company's primary methods for qualitative market assessments and market segmentation are top-down and bottom-up techniques. We take pride in our ability to use data triangulation to examine the market from three key angles: primary data mining, a specific statistical model and framework, and primary source data validation.

We carefully choose our original raw market data for analysis from a vast collection of data that has been compiled in our repository, as well as from sets of trustworthy and validated websites, analyst evaluations, news announcements, whitepapers, and reputable paid databases. Trade journals and in-depth surveys are used to collaborate on technical data and trends. Verified sources are used to assess pricing trends and market dynamics.

We use particular data simulation models to get our market estimates and forecasts. These models are developed and tailored to match the unique needs of every study. They are nimble and adaptable. For the most part, we use a joint combination of technological analysis, economic tools, domain experience, and economic techniques to forecast and estimate the market. In general, we favor using a bottom-up method to assess the worldwide market and calculate the anticipated rate of growth.

To verify our hypotheses and the results we have gotten, we carry out in-depth primary interviews, which include phone conversations, in-person discussions, and targeted group discussions. Extensive primary research has been conducted to verify our figures and forecast. These interviews also provide us with an objective view of the market, important information on companies operating in various markets, and up-to-date business scenarios.

Cancer Diagnostics Market based on Biopsy and Cytology Tests:
• Tumor Biomarkers
• Other Diagnostic Types
Cancer Diagnostics Market based on Application:
• Breast Cancer
• Lung Cancer
• Cervical Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Other Applications
Cancer Diagnostics Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
An important way to assess the hereditary risk of breast and ovarian cancers is to compare panel-based tests to BRCA1/2 genetic testing. Panel-based testing has a higher clinical value and yield when it comes to detecting inherited risks for various cancers, such as colon cancer and pheochromocytoma-paraganglioma. Individuals who have genetic anomalies associated with a hereditary cancer syndrome are more likely than the general population to develop some malignancies at an earlier age than is customary. Consequently, the requirement for early detection fuels the demand for panel testing even more. For example, VistaSeq, a hereditary cancer panel created to identify genetic abnormalities linked to over 50 hereditary cancer syndromes, is available from Laboratory Corporation of America Holdings.

Because of all the advantages of the test, including early cancer detection, biopsies are predicted to rise at the fastest compound annual growth rate (CAGR) between 2024 and 2030. A biopsy also aids in assessing the cancer's aggressiveness and propensity to spread to other organs. Depending on how far the cancer has gone, a biopsy aids in the choice of a particular treatment strategy.One of the main drivers of this market's expansion is the introduction of new products. For example, OverC was approved by the FDA in January 2023 and designated as a breakthrough device. Its intended purpose is the detection of lung, ovarian, pancreatic, liver, and esophageal cancers.

In 2023, North America held a 40.37% revenue share, dominating the market. The rising incidence of cancer in the United States and Canada, coupled with medical device makers' growing emphasis on creating innovative cancer-detecting equipment, is driving the market's expansion. Product releases are also important variables affecting market expansion. For example, Nanostics Inc. declared in July 2022 that it was beginning a clinical study on bladder cancer with the goal of figuring out the best markers for the condition's early identification. With the aid of the Nanostics ClarityDX diagnostic platform, the project seeks to develop a liquid biopsy test that is less invasive for the diagnosis of bladder cancer.

Due to a number of variables, including escalating healthcare reforms, the Asia Pacific market is anticipated to grow at the quickest CAGR between 2024 and 2030. One key element propelling market expansion is the rising incidence of cancer. For example, China has a high incidence, per a report released by PubMed Central in March 2022. Lung cancer was expected to be the most frequent type, with an estimated 4.8 million new cases in China by 2022. The high cancer prevalence in the nation is therefore anticipated to propel market expansion. Major global firms are growing in the Asia Pacific area, which should have a good effect on the expansion of the sector as a whole.The governments of Singapore and Taiwan provide financial and regulatory support.

• This report illustrates the most vital attributes of the Cancer Diagnostics Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Cancer Diagnostics Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Cancer Diagnostics Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cancer Diagnostics Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Biopsy and Cytology Tests: Market Size & Analysis
5.1. Overview
5.2. Tumor Biomarkers
5.3. Other Diagnostic Types
6. Application: Market Size & Analysis
6.1. Overview
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Cervical Cancer
6.5. Kidney Cancer
6.6. Liver Cancer
6.7. Pancreatic Cancer
6.8. Ovarian Cancer
6.9. Other Applications
7. Geography: Market Size & Analysis
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. Competitive Landscape
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. Vendor Profiles
9.1. EXACT SCIENCES CORPORATION
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. ARQUER DIAGNOSTICS LTD
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. BIOMARK DIAGNOSTICS INC.
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. BIOTHERANOSTICS
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. AGILENT TECHNOLOGIES
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. THERMO FISHER SCIENTIFIC
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. ILLUMINA
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. GE HEALTHCARE
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. QIAGEN N.V.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. ABBOTT LABORATORIES
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy

10. Analyst Opinion
11. Annexure
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. CANCER DIAGNOSTICS MARKET VALUE, BY BIOPSY AND CYTOLOGY TESTS, 2021-2030 (USD BILLION)
TABLE 2. CANCER DIAGNOSTICS MARKET VALUE FOR TUMOR BIOMARKERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. CANCER DIAGNOSTICS MARKET VALUE FOR OTHER DIAGNOSTIC TYPES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 5. CANCER DIAGNOSTICS MARKET VALUE FOR BREAST CANCER, 2021-2030 (USD BILLION)
TABLE 6. CANCER DIAGNOSTICS MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
TABLE 7. CANCER DIAGNOSTICS MARKET VALUE FOR CERVICAL CANCER, 2021-2030 (USD BILLION)
TABLE 8. CANCER DIAGNOSTICS MARKET VALUE FOR KIDNEY CANCER, 2021-2030 (USD BILLION)
TABLE 9. CANCER DIAGNOSTICS MARKET VALUE FOR PANCREATIC CANCER, 2021-2030 (USD BILLION)
TABLE 10. CANCER DIAGNOSTICS MARKET VALUE FOR LIVER CANCER, 2021-2030 (USD BILLION)
TABLE 11. CANCER DIAGNOSTICS MARKET VALUE FOR OTHER APPLICATIONS, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 14. NORTH AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 15. U.S CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 16. U.S CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 17. CANADA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 18. CANADA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 19. MEXICO CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 21. EUROPE CANCER DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 22. EUROPE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 23. EUROPE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 24. GERMANY CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 25. GERMANY CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 26. U.K CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 27. U.K CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 28. FRANCE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 29. FRANCE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 30. ITALY CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 31. ITALY CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 32. SPAIN CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 33. SPAIN CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 34. ROE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 35. ROE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 36. ASIA PACIFIC CANCER DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 37. ASIA PACIFIC CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 38. ASIA PACIFIC CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 39. CHINA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 40. CHINA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 41. INDIA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 42. INDIA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 43. JAPAN CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 44. JAPAN CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 45. REST OF APAC CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 46. REST OF APAC CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 47. LATIN AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. LATIN AMERICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 49. BRAZIL CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 50. BRAZIL CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 51. ARGENTINA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 52. ARGENTINA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 53. MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 54. MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 55. SAUDI ARABIA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 56. SAUDI ARABIA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 57. UAE CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. UAE CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 59. REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 60. REST OF MIDDLE EAST AND AFRICA CANCER DIAGNOSTICS MARKET VALUE, BY PRODUCT, 2021-2030 (USD BILLION)
TABLE 61. EXACT SCIENCES CORPORATION: FINANCIALS
TABLE 62. EXACT SCIENCES CORPORATION: PRODUCTS & SERVICES
TABLE 63. EXACT SCIENCES CORPORATION: RECENT DEVELOPMENTS
TABLE 64. ARQUER DIAGNOSTICS LTD: FINANCIALS
TABLE 65. ARQUER DIAGNOSTICS LTD: PRODUCTS & SERVICES
TABLE 66. ARQUER DIAGNOSTICS LTD: RECENT DEVELOPMENTS
TABLE 67. BIOMARK DIAGNOSTICS INC.: FINANCIALS
TABLE 68. BIOMARK DIAGNOSTICS INC.: PRODUCTS & SERVICES
TABLE 69. BIOMARK DIAGNOSTICS INC.: RECENT DEVELOPMENTS
TABLE 70. BIOTHERANOSTICS: FINANCIALS
TABLE 71. BIOTHERANOSTICS: PRODUCTS & SERVICES
TABLE 72. BIOTHERANOSTICS: RECENT DEVELOPMENTS
TABLE 73. AGILENT TECHNOLOGIES: FINANCIALS
TABLE 74. AGILENT TECHNOLOGIES: PRODUCTS & SERVICES
TABLE 75. AGILENT TECHNOLOGIES: RECENT DEVELOPMENTS
TABLE 76. THERMO FISHER SCIENTIFIC: FINANCIALS
TABLE 77. THERMO FISHER SCIENTIFIC: PRODUCTS & SERVICES
TABLE 78. THERMO FISHER SCIENTIFIC: RECENT DEVELOPMENTS
TABLE 79. ILLUMINA: FINANCIALS
TABLE 80. ILLUMINA: PRODUCTS & SERVICES
TABLE 81. ILLUMINA: DEVELOPMENTS
TABLE 82. GE HEALTHCARE: FINANCIALS
TABLE 83. GE HEALTHCARE: PRODUCTS & SERVICES
TABLE 84. GE HEALTHCARE: RECENT DEVELOPMENTS
TABLE 85. QIAGEN N.V.: FINANCIALS
TABLE 86. QIAGEN N.V.: PRODUCTS & SERVICES
TABLE 87. QIAGEN N.V.: RECENT DEVELOPMENTS
TABLE 88. ABBOTT LABORATORIES: FINANCIALS
TABLE 89. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 90. ABBOTT LABORATORIES: RECENT DEVELOPMENTS